Do not worry about your job. Seriously. The "reorg" people are taking about will only be a realignment of territory lines. It will be in place by the time you go to Chicago. Currently, territory lines are still based on cardiology business. They need to be re-drawn for the pain market. No headcount reduction except for people on final warning letters - they always get let go during these things. Hydexor was only supposed to bring in $20 million in 2017, so it's not like we're going bankrupt over the FDA's letter. Hope this helps. Keep up the good work.